MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake’s SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority
MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
Company Research
Source: GlobeNewswire
SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Global plaintiffs’ rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX) is December 15, 2025. “In specialized biotech cases, the core legal question is often whether the company’s claims about the study match the reality of the clinical data it was receiving,” said Reed Kathrein, the Hagens Berman partner leading the litigation. “The suit alleges that MoonLake concealed material adverse facts concerning SLK’s true clinical performance and its ability to differentiate itself from competitors like BIMZELX. We are scrutinizing whether the failure of the Nanobody structure to provide superior efficacy was misrepresented to investors. The firm urges investors in MoonLake who suffered significant losses to contact the firm now.” Legal Analysis: The Nanobody-Efficacy Disclosure Gap
Show less
Read more
Impact Snapshot
Event Time:
MLTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLTX alerts
High impacting MoonLake Immunotherapeutics - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MLTX
News
- SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsPR Newswire
- SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics (NASDAQ: MLTX)GlobeNewswire
- MoonLake Immunotherapeutics (MLTX) Investors are Encouraged to Act before the Upcoming December 15 Securities Fraud Deadline – Contact BFA Law if You Lost MoneyGlobeNewswire
- MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTXGlobeNewswire
- MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens BermanPR Newswire
MLTX
Earnings
- 11/5/25 - Miss
MLTX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form SCHEDULE
- 11/10/25 - Form SCHEDULE
- MLTX's page on the SEC website